Neutrons reveal unpredicted binding between SARS-CoV-2, hepatitis C antiviral drug
(DOE/Oak Ridge National Laboratory) Researchers at the Oak Ridge National Laboratory used neutron scattering to investigate the interactions between telaprevir, a drug used to treat hepatitis C viral infection, and the SARS-CoV-2 main protease, the enzyme responsible for enabling the virus to reproduce. Unforeseen changes in the electric charges were discovered in the drug binding site of the protease enzyme that were not predicted by prevailing computer simulations. The research provides key insights for advancing drug design and drug repurposing efforts to treat COVID-19. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 23, 2021 Category: International Medicine & Public Health Source Type: news
Roche awarded WHO prequalification for the HIV and HCV tests on the cobas 6800/8800 Systems
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the cobas ® HIV-1 and cobas® HCV Tests for use on the cobas® 6800/8800 Systems have been awarded World Health Organization (WHO) prequalification. WHO prequalification helps regulators and procurers in low and middle-income countries to identify products that meet high quality standards and are safe and su itable for their intended use. This is of benefit to healthcare professionals and patients, for whom quality assured IVDs are essential for effective diagnosis and monitoring of therapeutic efficiency. Increased access to diagnostic testi...
Source: Roche Media News - March 11, 2021 Category: Pharmaceuticals Source Type: news
Roche awarded WHO prequalification for the HIV and HCV tests on the cobas 6800/8800 Systems
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the cobas ® HIV-1 and cobas® HCV Tests for use on the cobas® 6800/8800 Systems have been awarded World Health Organization (WHO) prequalification. WHO prequalification helps regulators and procurers in low and middle-income countries to identify products that meet high quality standards and are safe and su itable for their intended use. This is of benefit to healthcare professionals and patients, for whom quality assured IVDs are essential for effective diagnosis and monitoring of therapeutic efficiency. Increased access to diagnostic testi...
Source: Roche Investor Update - March 11, 2021 Category: Pharmaceuticals Source Type: news
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have madeunprecedented progress in advancing treatments and vaccines to help fight COVID-19. At this time, three vaccines and several treatments have received emergency use authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) with one treatment receiving FDA approval. Additional candidates under investigation have also shown promise. (Source: The Catalyst)
Source: The Catalyst - March 8, 2021 Category: Pharmaceuticals Tags: Vaccines Coronavirus Source Type: news
La FDA advierte del riesgo de sufrir da ños hepáticos graves con los tratamientos de Viekira Pak y Technivie contra la hepatitis C
[10/22/2015] La Administraci ón de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) está advirtiendo que los tratamientos de Viekira Pak y Technivie contra la hepatitis C pueden causar daños hepáticos graves, sobre todo en pacientes con una enfermedad del hígado subyacente en etapa avanzada. En consecuencia, estamos exigiéndole al fabricante que añada nueva información sobre este riesgo de seguridad a las etiquetas de información farmacológica. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
